百奥泰生物制药股份有限公司

Bio-Thera Solutions, Ltd., headquartered in Guangzhou, China, is an international biopharmaceutical firm renowned for its scientific innovation. The company is committed to the development of cutting-edge therapeutics and biosimilar drugs aimed at addressing a wide array of medical challenges including cancer, autoimmune disorders, cardiovascular conditions, ophthalmological issues, and other life-threatening illnesses. As a pioneer in the realm of next-generation antibody drug research, Bio-Thera Solutions has driven several of its candidate drugs into advanced clinical stages of testing. Notably, the company's QLETLI? (Adalimumab), Prubece? (Bevacizumab), and Shuirili? (Tocilizumab) have received approval for commercialization in China, while TOFIDENCE? (Tocilizumab) and Avzivi? (Bevacizumab) have been authorized for use in both the US and China.

With a robust pipeline of over twenty investigational products at various stages of clinical development, Bio-Thera Solutions particularly emphasizes research in post-PD-1 era immunotherapy and the development of Antibody Drug Conjugates (ADCs) for targeted drug delivery. At the core of the company's mission is a commitment to patient welfare, driven by a dedication to innovating high-quality, safe, effective, and affordable treatments that address unmet medical needs.

For comprehensive details, please explore our official website or connect with us on Twitter and WeChat.